Volume 19 Issue 5, May 2022
Article Series: Nature Reviews Clinical Oncology
The changing landscape of phase I trials in oncology | Nature Reviews Clinical Oncology
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? | Nature Reviews Clinical Oncology
Volume 17 | Nature Reviews Clinical Oncology
Computational oncology — mathematical modelling of drug regimens for precision medicine | Nature Reviews Clinical Oncology
Volume 16 | Nature Reviews Clinical Oncology
Chimeric antigen receptor T-cell therapies for lymphoma | Nature Reviews Clinical Oncology
Volume 18 | Nature Reviews Clinical Oncology
Volume 17 | Nature Reviews Clinical Oncology
Imaging biomarker roadmap for cancer studies | Nature Reviews Clinical Oncology
Drug repurposing in oncology—patient and health systems opportunities | Nature Reviews Clinical Oncology
Volume 19 | Nature Reviews Clinical Oncology
Volume 18 | Nature Reviews Clinical Oncology
Volume 14 | Nature Reviews Clinical Oncology
2020 Nature Cancer Immunotherapy Calendar | OriGene
Work featured in Nature Reviews Clinical Oncology | Gevaert Lab | Stanford Medicine
Nature Reviews Clinical Oncology
Collections | Nature Reviews Clinical Oncology
Volume 7 | Nature Reviews Clinical Oncology
Volume 15 | Nature Reviews Clinical Oncology
Clinical overview of metronomic chemotherapy in breast cancer | Nature Reviews Clinical Oncology
Volume 15 | Nature Reviews Clinical Oncology
Volume 8 | Nature Reviews Clinical Oncology
Disseminated breast tumour cells: biological and clinical meaning | Nature Reviews Clinical Oncology
